Rallybio Files S-4 for Reverse Merger with Candid Therapeutics, Confirming Extreme Shareholder Dilution and $505.5M Financing
RLYB has more than doubled off its 52-week low of $1.761.
Summary
Rallybio Corp filed an S-4 registration statement detailing its reverse merger with Candid Therapeutics, which will result in existing Rallybio shareholders owning only 3.65% of the combined company, alongside a $505.5 million concurrent financing.
Key Events · M&A and Partnerships · RLYB
-
Reverse Merger Details
Rallybio Corp will merge with Candid Therapeutics, Inc., with Candid becoming a wholly-owned subsidiary and the combined entity being renamed Candid Therapeutics, Inc.
-
Extreme Shareholder Dilution
Existing Rallybio shareholders are projected to own approximately 3.65% of the combined company on a fully diluted basis, based on a Rallybio valuation of $47.5 million.
-
Substantial Concurrent Financing
The merger is accompanied by a $505.5 million concurrent financing, with investors expected to own 38.80% of the combined company.
-
Contingent Value Rights (CVRs)
Rallybio shareholders will receive CVRs tied to net proceeds from the disposition of Rallybio's legacy assets, including RLYB116 and proceeds from the REV102 sale.
Analysis · RLYB · Life Sciences
This S-4 filing provides comprehensive details for the previously announced reverse merger with Candid Therapeutics, a highly dilutive transaction for existing Rallybio shareholders. The merger will see Rallybio effectively acquired by Candid, with Rallybio shareholders retaining a minimal ownership stake of 3.65% in the combined entity, which will be renamed Candid Therapeutics, Inc. The transaction includes a substantial $505.5 million concurrent financing, critical for the combined company's future operations. While the financing provides a lifeline, the extreme dilution and loss of corporate identity represent a significant negative shift for current Rallybio investors. The filing also outlines a proposed reverse stock split and an increase in authorized shares, further underscoring the transformative nature of this event.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $9.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.8M. The 52-week trading range was $1.76 to $11.49. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.